Lithium Orotate 5 mg

Lithium Orotate 5 mg

Swanson4.7 (6,795 ratings)
Format:Capsule Quantity: 60 Capsule(s) · 60 servings
Goals
$10.99 $0.18 per serving

Product analysis

92 out of 100

Lithium Orotate 5 mg offers a simple, clearly labeled formula at a competitive serving cost. Mood benefits remain uncertain because findings for prescription lithium do not establish the effects of this supplement.

AI assessment of the formula, label and price. How scoring works

Nutrient Quality100

Lithium orotate is clearly identified and has a favorable compound form. The compound identity alone does not establish how it affects mood.

Ingredient Transparency100

The lithium amount and orotate form are both disclosed. That makes the contents straightforward to compare with other lithium supplements.

Value For Money80

The serving cost compares favorably. That describes affordability without establishing a mood benefit.

Customer Satisfaction90

Customer feedback is very favorable across thousands of ratings. The broad review base describes satisfaction, without establishing effectiveness or safety.

Product Focus82

Lithium is the sole ingredient directed at mood support. A general mood benefit from the supplemental serving remains unestablished, and prescription-lithium findings do not resolve that uncertainty.

Format
Capsule
Container
60 Capsule(s)
Per serving
$0.18
Customer rating
4.7 · 6,795 ratings
Report analysis

Goals

Mood Support
Impact
Highest effect
A+ Ingredient FitC- PathwaysB+ EvidenceA+ Formulation Logic

Lithium is the sole mood-directed ingredient, declared as lithium orotate. The saved findings recognize its amount and a connection to brain plasticity, but prescription-lithium findings do not establish mood benefits from this supplement exposure. The supplied information does not demonstrate a general mood effect for 5 mg of supplemental lithium per serving.

How this product is rated for Mood Support

Ingredient fit100

Lithium provide the main mood-related connections. The recognized ingredients are concentrated in this area.
Goal fit
The recognized ingredients are focused on mood-related roles; the product’s links to other goals also affect that focus.
Dose adequacy
The declared lithium amount receives full amount recognition, which does not establish benefit from supplemental lithium.

Pathways56

The strongest represented area is Neuroinflammation and neuroplasticity. The wider coverage includes Neuroinflammation and neuroplasticity.
Depth
Neuroinflammation and neuroplasticity is the strongest represented area in the saved findings; this does not independently establish a mood effect.
Breadth
One area reaches the saved coverage threshold, describing the range represented rather than proven benefits.

Evidence82

Lithium leads the evidence finding. Its specific population and preparation limits remain relevant, even where the ingredient amount and preparation are recognized.
Evidence strength
Lithium leads the saved evidence finding; its population and preparation limits still govern the mood claims that can be made.
Studied preparation
The saved findings recognize the qualifying preparations, but that does not make every form interchangeable or establish routine mood benefit.

Formulation logic100

The recognized ingredients meet the supplied partner requirements, with no specified ingredient conflict matched. All recognized ingredients meet the amount threshold used in these findings.
Partner coverage
The recognized ingredients can contribute independently or have the partner required by the supplied findings; no extra combination benefit is established.
Conflicts
No specified ingredient conflict was matched in the supplied findings; this does not establish medication compatibility.
Effective doses
The recognized ingredients meet the saved amount threshold; this is not proof that each serving produces a mood benefit.
Study evidence
Lithium Supportive 197 studies

Ingredients

IngredientAmount per servingScore
Lithium (Lithium Orotate)
5 mg 96
Adults 18–50 Women
Report overview
A+ Active Ingredient Quality & BioavailabilityA+ Dose, Safety & Label TransparencyB+ Value
A serving provides 5 mg of lithium from lithium orotate. The whole-product serving costs about $0.18.
How this ingredient is rated

Active Ingredient Quality & Bioavailability100

Lithium Orotate is the named chemical form; the saved information does not establish that it is absorbed better than other forms.
Lithium Compound Optimization
Lithium Orotate is the named chemical form; the saved information does not establish that it is absorbed better than other forms.

Dose, Safety & Label Transparency100

The stated 5 mg per serving is the amount of lithium itself, making it possible to compare with other amounts given on the same basis.
Elemental Disclosure Precision
The amount of lithium itself is stated as 5 mg per serving, rather than only the weight of its source compound.
Dosage Appropriateness
A serving contains 5 mg of lithium.

Value80

The whole-product serving costs about $0.18 and supplies 5 mg of lithium.
Cost Per Serving Efficiency
The whole-product serving costs about $0.18 and supplies 5 mg of lithium.
Report alternatives

Sources

Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.

  1. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
    Yatham LN; Kennedy SH; Parikh SV; Schaffer A; Bond DJ; Frey BN; Sharma V; Goldstein BI; Rej S; Beaulieu S; Alda M; MacQueen G; Milev RV; Ravindran A; O'Donovan C; McIntosh D; Lam RW; Vazquez G; Kapczinski F; McIntyre RS; Kozicky J; Kanba S; Lafer B; Suppes T; Calabrese JR; Vieta E; Malhi G; Post RM; Berk M · Bipolar disorders · 2019
    Guideline / consensusMood Support forLithium
  2. GERI-BD: A Randomized Double-Blind Controlled Trial of Lithium and Divalproex in the Treatment of Mania in Older Patients With Bipolar Disorder.
    Young RC; Mulsant BH; Sajatovic M; Gildengers AG; Gyulai L; Al Jurdi RK; Beyer J; Evans J; Banerjee S; Greenberg R; Marino P; Kunik ME; Chen P; Barrett M; Schulberg HC; Bruce ML; Reynolds CF; Alexopoulos GS; GERI-BD Study Group · The American journal of psychiatry · 2017
    Randomized trial224 participantsMood Support forLithium
  3. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder.
    Bowden CL; Calabrese JR; Sachs G; Yatham LN; Asghar SA; Hompland M; Montgomery P; Earl N; Smoot TM; DeVeaugh-Geiss J; Lamictal 606 Study Group · Archives of general psychiatry · 2003
    Randomized trial175 participantsMood Support forLithium
  4. Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials.
    Kishi T; Ikuta T; Matsuda Y; Sakuma K; Okuya M; Mishima K; Iwata N · Molecular psychiatry · 2022
    Meta-analysis9,821 participants41 studies pooledMood Support forLithium
  5. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder.
    Goodwin GM; Bowden CL; Calabrese JR; Grunze H; Kasper S; White R; Greene P; Leadbetter R · The Journal of clinical psychiatry · 2004
    Meta-analysis638 participants2 studies pooledMood Support forLithium